leadf
logo-loader
viewPreveCeutical Medical Inc.
(
CSE:PREVOTCQB:PRVCF
)

PreveCeutical seeing significant hospital interest for breakthrough Cannabidiol treatment

Stephen Van Deventer, chairman and CEO of PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) and chief research officer Dr Harry Parekh discuss with Proactive the health sciences specialist's four exciting programmes.

Their most advanced is centred around Cannabidiol (CBD) - a non-psychoactive compound found in the cannabis plant and is now widely used to treat chronic pain, multiple sclerosis and other conditions.

Some evidence even suggests it can prevent symptoms of Alzheimer’s and appears to promote the death of cancer cells.

Quick facts: PreveCeutical Medical Inc.

Follow
CSE:PREV

Price: 0.025 CAD

Market Cap: $12.79 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 07/23/2020

2 min read